Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Multimodal analyses of vitiligo skin idenitfy tissue characteristics of stable disease
Jessica Shiu, … , Mihaela Balu, Anand K. Ganesan
Jessica Shiu, … , Mihaela Balu, Anand K. Ganesan
Published June 2, 2022
Citation Information: JCI Insight. 2022;7(13):e154585. https://doi.org/10.1172/jci.insight.154585.
View: Text | PDF
Research Article Dermatology

Multimodal analyses of vitiligo skin idenitfy tissue characteristics of stable disease

  • Text
  • PDF
Abstract

Vitiligo is an autoimmune skin disease characterized by the destruction of melanocytes by autoreactive CD8+ T cells. Melanocyte destruction in active vitiligo is mediated by CD8+ T cells, but the persistence of white patches in stable disease is poorly understood. The interaction between immune cells, melanocytes, and keratinocytes in situ in human skin has been difficult to study due to the lack of proper tools. We combine noninvasive multiphoton microscopy (MPM) imaging and single-cell RNA-Seq (scRNA-Seq) to identify subpopulations of keratinocytes in stable vitiligo patients. We show that, compared with nonlesional skin, some keratinocyte subpopulations are enriched in lesional vitiligo skin and shift their energy utilization toward oxidative phosphorylation. Systematic investigation of cell-to-cell communication networks show that this small population of keratinocyte secrete CXCL9 and CXCL10 to potentially drive vitiligo persistence. Pseudotemporal dynamics analyses predict an alternative differentiation trajectory that generates this new population of keratinocytes in vitiligo skin. Further MPM imaging of patients undergoing punch grafting treatment showed that keratinocytes favoring oxidative phosphorylation persist in nonresponders but normalize in responders. In summary, we couple advanced imaging with transcriptomics and bioinformatics to discover cell-to-cell communication networks and keratinocyte cell states that can perpetuate inflammation and prevent repigmentation.

Authors

Jessica Shiu, Lihua Zhang, Griffin Lentsch, Jessica L. Flesher, Suoqin Jin, Christopher Polleys, Seong Jin Jo, Craig Mizzoni, Pezhman Mobasher, Jasmine Kwan, Francisca Rius-Diaz, Bruce J. Tromberg, Irene Georgakoudi, Qing Nie, Mihaela Balu, Anand K. Ganesan

×

Figure 10

Keratinocyte energy utilization normalize in vitiligo patients who respond to punch grafting treatment but persist in nonresponders.

Options: View larger image (or click on image) Download as PowerPoint
Keratinocyte energy utilization normalize in vitiligo patients who respo...
(A) Representative clinical images from vitiligo patients undergoing punch grafting treatment. Clinical responder on top and nonresponder on the bottom. (B) Average mitochondrial clustering values (β values) based on Z stacks from 6 vitiligo patients as a function of depth for responders and nonresponders at baseline are shown as spline fits. Patients were followed and imaged again after 10 weeks. Average mitochondrial clustering values (β values) for clinical responders (n = 3) and nonresponders (n = 3) are shown. (C) Distribution of β variability values (right) in punch grafting responders and nonresponders (n = 6); each value corresponds to a Z stack of images acquired. *P < 0.05 by t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts